当前蛋白身份:P30556 重新检索
本组结构的主要差异维度
构建体不同 突变/修饰不同 组装状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
4YAY XFEL structure of human Angiotensin Receptor 提交 2015-02-18 Assembly 1 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 2–319(318 aa)
突变:M1007W, H1102I, R1106L ZD7 5,7-diethyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-3,4-dihydro-1,6-naphthyridin-2(1H)-one × 1 X-RAY DIFFRACTION
X-ray结晶条件 LIPIDIC CUBIC PHASE;pH 5;294 K;100 mM sodium citrate, pH 5.0, 450 mM NH4H2PO4, 28% (v/v) PEG400 and 4% (v/v) DMSO
分辨率 2.90 Å R-free 0.274
4ZUD Crystal Structure of Human Angiotensin Receptor in Complex with Inverse Agonist Olmesartan at 2.8A resolution. 提交 2015-05-15 Assembly 1 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 2–6(5 aa)
链 A 17–315(299 aa)
突变:M1007W, H1102I, R1106L 突变:M1007W, H1102I, R1106L OLM Olmesartan × 1 X-RAY DIFFRACTION
X-ray结晶条件 LIPIDIC CUBIC PHASE;pH 5;293 K;100 mM sodium citrate, pH 5.0, 400 mM KH2PO4, 25% (v/v) PEG400, and 6% (v/v) DMSO
分辨率 2.80 Å R-free 0.234
6DO1 Structure of nanobody-stabilized angiotensin II type 1 receptor bound to S1I8 提交 2018-06-08 Assembly 1 信息不足 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 2–226(225 aa)
链 A 227–319(93 aa)
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CL CHLORIDE ION × 3 OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2 X-RAY DIFFRACTION
X-ray结晶条件 LIPIDIC CUBIC PHASE;pH 8;293.15 K;Protein was reconstituted with a 10:1 (w:w) mix of monoolein and cholesterol. Crystals were grown in cubic phase sandwich plates with using 100 mM Tris pH 8.0, 15-25 mM MgCl2, and 28-29% PEG 300
分辨率 2.90 Å R-free 0.359
6DO1 Structure of nanobody-stabilized angiotensin II type 1 receptor bound to S1I8 提交 2018-06-08 Assembly 2 信息不足 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 B 2–226(225 aa)
链 B 227–319(93 aa)
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CL CHLORIDE ION × 2 OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 3 X-RAY DIFFRACTION
X-ray结晶条件 LIPIDIC CUBIC PHASE;pH 8;293.15 K;Protein was reconstituted with a 10:1 (w:w) mix of monoolein and cholesterol. Crystals were grown in cubic phase sandwich plates with using 100 mM Tris pH 8.0, 15-25 mM MgCl2, and 28-29% PEG 300
分辨率 2.90 Å R-free 0.359
6OS0 Structure of synthetic nanobody-stabilized angiotensin II type 1 receptor bound to angiotensin II 提交 2019-05-01 Assembly 1 信息不足 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 A 2–226(225 aa)
链 A 227–319(93 aa)
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 LIPIDIC CUBIC PHASE;pH 7.6;293 K;Protein complex was reconstituted with a 10:1 (w/w) mixture of monoolein and cholesterol. Crystals were grown in 100 mM Tris pH 7.6, 10 mM MgCl2, 25-26% PEG 300
分辨率 2.90 Å R-free 0.318
6OS1 Structure of synthetic nanobody-stabilized angiotensin II type 1 receptor bound to TRV023 提交 2019-05-01 Assembly 1 信息不足 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 A 2–226(225 aa)
链 A 227–319(93 aa)
未记录 OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 6 CLR CHOLESTEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 LIPIDIC CUBIC PHASE;pH 8;293 K;Protein complex was reconstituted with a 10:1 (w/w) mixture of monoolein and cholesterol. Crystals were grown in 100 mM Tris pH 8, 50-70 mM MgCl2, 30% PEG 300, 2-4% 1,3-butanediol
分辨率 2.79 Å R-free 0.282
6OS2 Structure of synthetic nanobody-stabilized angiotensin II type 1 receptor bound to TRV026 提交 2019-05-01 Assembly 1 信息不足 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 A 2–226(225 aa)
链 A 227–319(93 aa)
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 6 CLR CHOLESTEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 LIPIDIC CUBIC PHASE;pH 8;293 K;Protein complex was reconstituted with a 10:1 (w/w) mixture of monoolein and cholesterol. Crystals were grown in 100 mM Tris pH 8, 65 mM MgCl2, 26-28% PEG 300, 4.5% 1,3-butanediol
分辨率 2.70 Å R-free 0.285
8TH3 Structure of AT118-H Nanobody Antagonist in Complex with the Angiotensin II Type I Receptor 提交 2023-07-13 Assembly 1 信息不足 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 2–226(225 aa)
链 A 235–319(85 aa)
链 B 2–226(225 aa)
链 B 235–319(85 aa)
未记录 Y01 CHOLESTEROL HEMISUCCINATE × 2 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.4;20 mM HEPES, pH 7.4, 100 mM NaCl, 0.05% GDN, 0.005% CHS
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.00 Å
8TH4 Structure of AT118-L Nanobody Antagonist in Complex with the Angiotensin II Type I Receptor and Losartan 提交 2023-07-13 Assembly 1 信息不足 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 2–226(225 aa)
链 A 235–319(85 aa)
未记录 LSN [2-butyl-5-chloranyl-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.4;20 mM HEPES, pH 7.4, 100 mM NaCl, 0.05% GDN, 0.005% CHS
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.30 Å
9EAH Structure of nanobody AT209 in complex with the olmesartan-bound angiotensin II type I receptor (AT1R) 提交 2024-11-11 Assembly 1 信息不足 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 2–226(225 aa)
链 A 235–319(85 aa)
链 B 2–226(225 aa)
链 B 235–319(85 aa)
突变:M232W, H327I, R331L 突变:M232W, H327I, R331L 突变:M232W, H327I, R331L 突变:M232W, H327I, R331L OLM Olmesartan × 1 CLR CHOLESTEROL × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.10 Å
9EAI Structure of nanobody AT206 in complex with the losartan-bound angiotensin II type I receptor (AT1R) 提交 2024-11-11 Assembly 1 信息不足 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 2–226(225 aa)
链 A 235–319(85 aa)
链 B 2–226(225 aa)
链 B 235–319(85 aa)
突变:M232W, H327I, R331L 突变:M232W, H327I, R331L 突变:M232W, H327I, R331L 突变:M232W, H327I, R331L LSN [2-butyl-5-chloranyl-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol × 1 Y01 CHOLESTEROL HEMISUCCINATE × 2 CLR CHOLESTEROL × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.10 Å
9EAJ Structure of nanobody AT206 in complex with the angiotensin II type I receptor (AT1R) 提交 2024-11-11 Assembly 1 信息不足 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 2–226(225 aa)
链 A 235–319(85 aa)
链 B 2–226(225 aa)
链 B 235–319(85 aa)
突变:M232W, H327I, R331L 突变:M232W, H327I, R331L 突变:M232W, H327I, R331L 突变:M232W, H327I, R331L 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.20 Å